Making the case for the development of a vaccination against hepatitis E virus

Liver International

Volumn 35, Issue 2, 2015, Pages 311-316

  Haffar, Samir ^a   Bazerbachi, Fateh ^b   Lake, John R ^b  

^a Department of Gastroenterology   (Syrian Arab Republic)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Hepatitis E virus (HEV); HEV vaccine; Primary prevention; Vaccination; Viral hepatitis

Indexed keywords

HEPATITIS VACCINE;

GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; INFECTION PREVENTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VACCINATION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; VIRUS GENOME;

CLINICAL TRIALS AS TOPIC; GENOME, VIRAL; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; VIRAL HEPATITIS VACCINES;

EID: 84921614213     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12590     Document Type: Review

References (33)

1. Krawczynski K. Hepatitis E. Hepatology 1993; 17: 932-41.
2. Hepatitis E vaccine: why wait? Lancet 2010; 376: 845.
3. Khuroo MS, Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepatitis 2003; 10: 61-9.
4. Khuroo MS. Discovery of hepatitis E: the epidemic non-A, non-B hepatitis 30 years down the memory lane. Virus Res 2011; 161: 3-14.
5. Teshale EH, Howard CM, Grytdal SP, et al. Hepatitis E epidemic, Uganda. Emerg Infect Dis 2010; 16: 126-9.
6. Miyamura T. Hepatitis E virus infection in developed countries. Virus Res 2011; 161: 40-6.
7. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012; 55: 988-97.
8. Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 1983; 20: 23-31.
9. Reyes GR, Yarbough PO, Tam AW, et al. Hepatitis E virus (HEV): the novel agent responsible for enterically transmitted non-A, non-B hepatitis. Gastroenterol Jpn 1991; 26(Suppl. 3): 142-7.
10. Krawczynski K. Hepatitis E vaccine-ready for prime time? New Engl J Med 2007; 356: 949-51.
11. Zhang J, Gu Y, Ge SX, et al. Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. Vaccine 2005; 23: 2881-92.
12. Xing L, Li TC, Mayazaki N, et al. Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J Biochem 2010; 285: 33175-83.
13. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. New Engl J Med 2012; 367: 1237-44.
14. Kamili S. Toward the development of a hepatitis E vaccine. Virus Res 2011; 161: 93-100.
15. Aggarwal R, Jameel S. Hepatitis E vaccine. Hep Intl 2008; 2: 308-15.
16. Holla RP, Ahmad I, Ahmad Z, Jameel S. Molecular virology of hepatitis E virus. Semin Liver Dis 2013; 33: 3-14.
17. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. New Engl J Med 2007; 356: 895-903.
18. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902.
19. Thomas DBMPM, Arun JS. Zakim and Boyer's Hepatology: A Textbook of Liver Disease, 6th edn. Philadelphia, PA: Saunders, 2011.
20. Riveiro-Barciela M, Rodriguez-Frias F, Buti M. Hepatitis E virus: new faces of an old infection. Ann Hepatol 2013; 12: 861-70.
21. Zhang J, Zhang XF, Zhou C, et al. Protection against hepatitis E virus infection by naturally acquired and vaccine induced immunity. Clin Microbiol Infect 2013. doi: 10.1111/1469-0691.12419 [Epub ahead of print].
22. Wu T, Li SW, Zhang J, et al. Hepatitis E vaccine development: a 14 year odyssey. Hum Vaccin Immunother 2012; 8: 823-7.
23. Riedmann EM. Chinese biotech partnership brings first hepatitis E vaccine to the market. Hum Vaccin Immunother 2012; 8: 1743-4.
24. Ramachandran J, Eapen CE, Kang G, et al. Hepatitis E superinfection produces severe decompensation in patients with chronic liver disease. J Gastroenterol Hepatol 2004; 19: 134-8.
25. Kumar AS, Kumar SP, Singh R, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007; 46: 387-94.
26. Dalton HR, Hazeldine S, Banks M, Ijaz S, Bendall R. Locally acquired hepatitis E in chronic liver disease. Lancet 2007; 369: 1260.
27. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet 2012; 379: 2477-88.
28. Kim JJ. The role of cost-effectiveness in U.S. vaccination policy. New Engl J Med 2011; 365: 1760-1.
29. Das A, Sinha M. A cost-effectiveness analysis of a candidate vaccine against hepatitis E virus using the institute of medicine model. Am J Gastroenterol 2001; 96 (9, Suppl. 1): S263.
30. Riedmann EM. Human vaccines & immunotherapeutics: news. Hum Vaccin Immunother 2014; 10: 252-255.
31. Wierzba TF, Panzner U. Report on the International symposium on hepatitis E, Seoul, South Korea, 2010. Emerg Infect Dis 2012.
32. Kumar S, Subhadra S, Singh B, Panda BK. Hepatitis E virus: the current scenario. Int J Infect Dis: IJID: Official Publication of the International Society for Infectious Diseases 2013; 17: e228-33.
33. Acharya SK, Panda SK. Hepatitis E: water, water everywhere - now a global disease. J Hepatol 2011; 54: 9-11.